Spyre Therapeutics (SYRE) said late Monday it has priced a public offering of about 14.9 million shares at $18.50 each for expected gross proceeds of $275 million.
The company granted the underwriters a 30-day option to purchase up to about 2.2 million additional shares.
The offering is expected to close Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.